BidaskClub upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a hold rating in a report released on Thursday.

Several other research firms have also recently weighed in on LXRX. Gabelli cut Lexicon Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday. Zacks Investment Research cut Lexicon Pharmaceuticals from a buy rating to a hold rating in a report on Friday, January 18th. ValuEngine raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday. Wedbush increased their price target on Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the company an outperform rating in a report on Monday, March 4th. Finally, Citigroup reissued a buy rating and set a $14.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, January 22nd. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $20.38.

LXRX stock traded up $0.27 during midday trading on Thursday, hitting $7.60. The company’s stock had a trading volume of 6,048 shares, compared to its average volume of 870,616. The stock has a market capitalization of $789.14 million, a PE ratio of -5.91 and a beta of 0.70. Lexicon Pharmaceuticals has a 12 month low of $4.26 and a 12 month high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.12. The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $13.33 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The company’s revenue was down 49.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.27) EPS. As a group, analysts predict that Lexicon Pharmaceuticals will post -1.28 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Lexicon Pharmaceuticals by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,834,766 shares of the biopharmaceutical company’s stock worth $40,917,000 after purchasing an additional 72,640 shares during the period. MetLife Investment Advisors LLC raised its holdings in Lexicon Pharmaceuticals by 49.8% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 11,862 shares during the period. D.A. Davidson & CO. bought a new position in Lexicon Pharmaceuticals in the 4th quarter worth $87,000. Virtus ETF Advisers LLC raised its holdings in Lexicon Pharmaceuticals by 35.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 82,295 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 21,567 shares during the period. Finally, Wedbush Securities Inc. raised its holdings in Lexicon Pharmaceuticals by 39.4% in the 4th quarter. Wedbush Securities Inc. now owns 174,442 shares of the biopharmaceutical company’s stock worth $1,158,000 after purchasing an additional 49,312 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: Growth Stocks, What They Are, What They Are Not

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.